The US Food and Drug Administration rejected Neuralink Corp.’s plans for a human clinical trials of its Link brain interface implant in 2022, according to an investigative report from Reuters.
Over the last four years, Neuralink CEO Elon Musk has repeatedly claimed that the company was ready to start human clinical trials of Link for motor, sensory, visual or neurological impairments – including a presentation to investors in late November
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?